A Clinical Study of Intravenous Immunoglobulin

• Status: Completed
• Trial end date: 2009-08-01

Summary

The purpose of this study is to measure the pharmacokinetics, efficacy and safety of Immune Globulin Intravenous (Human) [IGIV], 5% Solution Omr-IgG-am™ in patients with primary immunodeficiency diseases.

• Phase: Phase 3

Details

• Lead Sponsor: FFF Enterprises
• Collaborator: OMRIX Biopharmaceuticals
• Treatments: Antibodies; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin